DHR Jan 2025 190.000 call
| Previous close | 76.50 |
| Open | 74.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 190.00 |
| Expiry date | 2025-01-17 |
| Day's range | 74.15 - 76.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksDanaher (DHR) Rides on Business Strength Amid Headwinds
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
PR NewswireDanaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
ZacksDanaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
